Equities
  • Price (USD)9.68
  • Today's Change0.000 / 0.00%
  • Shares traded11.25k
  • 1 Year change-21.29%
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024 15:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in JPY

The one analyst offering a 12 month price target expects Astellas Pharma Inc share price to rise to 50.00 in the next year from the last price of 9.68.
High416.5%50.00
Med416.5%50.00
Low416.5%50.00

Dividends in JPY

Historical dividend information is not available for Astellas Pharma Inc.
Div growth (TTM)16.67%
More ▼

Earnings history & estimates in JPY

On Oct 30, 2024, Astellas Pharma Inc reported 2nd quarter 2025 earnings of 20.06 per share.
The next earnings announcement is expected on Feb 02, 2025.
Average growth rate-4.48%
Astellas Pharma Inc reported annual 2024 earnings of 9.51 per share on Apr 25, 2024.
Average growth rate-33.99%
More ▼

Revenue history & estimates in JPY

-32768 had 2nd quarter 2025 revenues of 462.50m. This bettered the 452.53m consensus of the 3 analysts covering the company. This was 23.34% above the prior year's 2nd quarter results.
Average growth rate+4.43%
-32768 had revenues for the full year 2024 of 1.60bn. This was 5.60% above the prior year's results.
Average growth rate+5.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.